表没食子儿茶素-3-没食子酸酯抗非酒精性脂肪肝的临床前证据构建：荟萃分析和机器学习研究

IF 6.7 1区医学 Q1 CHEMISTRY, MEDICINAL

Phytomedicine Pub Date : 2025-04-10 DOI:10.1016/j.phymed.2025.156651

Yuanhao Zhang , Jianguo Li , Zexin Wang , Jie Chen , Maoyuan Zhao , Cui Guo , Tingyao Wang , Ruilin Li , Hebin Zhang , Xiao Ma , Yueqiang Wen , Jinhao Zeng , Thomas Efferth

{"title":"表没食子儿茶素-3-没食子酸酯抗非酒精性脂肪肝的临床前证据构建：荟萃分析和机器学习研究","authors":"Yuanhao Zhang , Jianguo Li , Zexin Wang , Jie Chen , Maoyuan Zhao , Cui Guo , Tingyao Wang , Ruilin Li , Hebin Zhang , Xiao Ma , Yueqiang Wen , Jinhao Zeng , Thomas Efferth","doi":"10.1016/j.phymed.2025.156651","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant health concern worldwide, exhibiting an increasing incidence that necessitates immediate intervention. Epigallocatechin-3-gallate (EGCG) has shown significant pharmacological benefits for liver diseases, including NAFLD. However, its efficacy in this context has not been systematically evaluated.</div></div><div><h3>Purpose</h3><div>This meta-analysis aimed to consolidate preclinical evidence on the effectiveness and mechanisms of EGCG in treating NAFLD.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive literature search for preclinical studies from the inception of each database to April 2024, including Excerpta Medica Database, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and China Science and Technology Journal Database. These studies were manually screened based on predefined criteria. Data extraction was followed by pooled effect size calculations using Stata 16.0. A machine learning approach was also utilized to examine the temporal relationships among variables.</div></div><div><h3>Results</h3><div>Seventeen studies, involving 293 animals, were analyzed. Our analysis indicates that EGCG significantly reduces ALT, AST, hepatic triglyceride, serum TG, hepatic TC, serum TC. The targets of EGCG may include antioxidants, regulation of lipid metabolism, anti-inflammation, improvement of insulin resistance, and inhibition of hepatic fibrosis. EGCG exerted its effects on NAFLD by modulating key signaling pathways, including PI3K/Akt/AMPK, TGF-β/Smad, Nrf2, NF-κB, and ROS/MAPK, highlighting its multifaceted mechanisms of action. The machine learning methods employed to ascertain the temporal relationship between the intervention and the outcome indicated that the optimal duration of the intervention was 10 to 15 weeks.</div></div><div><h3>Conclusions</h3><div>The efficacy of EGCG in treating NAFLD has been predicted within a time frame of 10–15 weeks. It may exert its effects primarily through the NF-κB and Nrf2 pathways, which regulate the ROS phenotype. EGCG may represent a promising target for the treatment of NAFLD.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"142 ","pages":"Article 156651"},"PeriodicalIF":6.7000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preclinical evidence construction for epigallocatechin-3-gallate against non-alcoholic fatty liver disease: a meta-analysis and machine learning study\",\"authors\":\"Yuanhao Zhang , Jianguo Li , Zexin Wang , Jie Chen , Maoyuan Zhao , Cui Guo , Tingyao Wang , Ruilin Li , Hebin Zhang , Xiao Ma , Yueqiang Wen , Jinhao Zeng , Thomas Efferth\",\"doi\":\"10.1016/j.phymed.2025.156651\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant health concern worldwide, exhibiting an increasing incidence that necessitates immediate intervention. Epigallocatechin-3-gallate (EGCG) has shown significant pharmacological benefits for liver diseases, including NAFLD. However, its efficacy in this context has not been systematically evaluated.</div></div><div><h3>Purpose</h3><div>This meta-analysis aimed to consolidate preclinical evidence on the effectiveness and mechanisms of EGCG in treating NAFLD.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive literature search for preclinical studies from the inception of each database to April 2024, including Excerpta Medica Database, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and China Science and Technology Journal Database. These studies were manually screened based on predefined criteria. Data extraction was followed by pooled effect size calculations using Stata 16.0. A machine learning approach was also utilized to examine the temporal relationships among variables.</div></div><div><h3>Results</h3><div>Seventeen studies, involving 293 animals, were analyzed. Our analysis indicates that EGCG significantly reduces ALT, AST, hepatic triglyceride, serum TG, hepatic TC, serum TC. The targets of EGCG may include antioxidants, regulation of lipid metabolism, anti-inflammation, improvement of insulin resistance, and inhibition of hepatic fibrosis. EGCG exerted its effects on NAFLD by modulating key signaling pathways, including PI3K/Akt/AMPK, TGF-β/Smad, Nrf2, NF-κB, and ROS/MAPK, highlighting its multifaceted mechanisms of action. The machine learning methods employed to ascertain the temporal relationship between the intervention and the outcome indicated that the optimal duration of the intervention was 10 to 15 weeks.</div></div><div><h3>Conclusions</h3><div>The efficacy of EGCG in treating NAFLD has been predicted within a time frame of 10–15 weeks. It may exert its effects primarily through the NF-κB and Nrf2 pathways, which regulate the ROS phenotype. EGCG may represent a promising target for the treatment of NAFLD.</div></div>\",\"PeriodicalId\":20212,\"journal\":{\"name\":\"Phytomedicine\",\"volume\":\"142 \",\"pages\":\"Article 156651\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phytomedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0944711325002910\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytomedicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0944711325002910","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

背景：非酒精性脂肪性肝病（NAFLD）已成为世界范围内一个重要的健康问题，其发病率不断上升，需要立即进行干预。表没食子儿茶素-3-没食子酸酯（EGCG）已显示出对肝脏疾病（包括NAFLD）的显著药理学益处。然而，其在这方面的效力尚未得到系统评价。目的本荟萃分析旨在巩固EGCG治疗NAFLD的有效性和机制的临床前证据。方法对各数据库建立至2024年4月的临床前研究进行文献检索，包括：摘录医学数据库、PubMed、Web of Science、Cochrane图书馆、中国国家知识基础设施、万方、中国科技期刊库。这些研究是根据预先确定的标准进行人工筛选的。数据提取后，使用Stata 16.0计算合并效应大小。还利用机器学习方法来检查变量之间的时间关系。结果共分析了17项研究，涉及293只动物。我们的分析表明，EGCG显著降低ALT、AST、肝甘油三酯、血清TG、肝TC、血清TC。EGCG的作用靶点可能包括抗氧化剂、调节脂质代谢、抗炎症、改善胰岛素抵抗和抑制肝纤维化。EGCG通过调节PI3K/Akt/AMPK、TGF-β/Smad、Nrf2、NF-κB、ROS/MAPK等关键信号通路对NAFLD发挥作用，其作用机制具有多面性。用于确定干预与结果之间时间关系的机器学习方法表明，干预的最佳持续时间为10至15周。结论EGCG治疗NAFLD的疗效预计在10-15周。它可能主要通过调节ROS表型的NF-κB和Nrf2途径发挥作用。EGCG可能是治疗NAFLD的一个有希望的靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Preclinical evidence construction for epigallocatechin-3-gallate against non-alcoholic fatty liver disease: a meta-analysis and machine learning study

查看原文本刊更多论文

Preclinical evidence construction for epigallocatechin-3-gallate against non-alcoholic fatty liver disease: a meta-analysis and machine learning study

Background

Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant health concern worldwide, exhibiting an increasing incidence that necessitates immediate intervention. Epigallocatechin-3-gallate (EGCG) has shown significant pharmacological benefits for liver diseases, including NAFLD. However, its efficacy in this context has not been systematically evaluated.

Purpose

This meta-analysis aimed to consolidate preclinical evidence on the effectiveness and mechanisms of EGCG in treating NAFLD.

Methods

We conducted a comprehensive literature search for preclinical studies from the inception of each database to April 2024, including Excerpta Medica Database, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and China Science and Technology Journal Database. These studies were manually screened based on predefined criteria. Data extraction was followed by pooled effect size calculations using Stata 16.0. A machine learning approach was also utilized to examine the temporal relationships among variables.

Results

Seventeen studies, involving 293 animals, were analyzed. Our analysis indicates that EGCG significantly reduces ALT, AST, hepatic triglyceride, serum TG, hepatic TC, serum TC. The targets of EGCG may include antioxidants, regulation of lipid metabolism, anti-inflammation, improvement of insulin resistance, and inhibition of hepatic fibrosis. EGCG exerted its effects on NAFLD by modulating key signaling pathways, including PI3K/Akt/AMPK, TGF-β/Smad, Nrf2, NF-κB, and ROS/MAPK, highlighting its multifaceted mechanisms of action. The machine learning methods employed to ascertain the temporal relationship between the intervention and the outcome indicated that the optimal duration of the intervention was 10 to 15 weeks.

Conclusions

The efficacy of EGCG in treating NAFLD has been predicted within a time frame of 10–15 weeks. It may exert its effects primarily through the NF-κB and Nrf2 pathways, which regulate the ROS phenotype. EGCG may represent a promising target for the treatment of NAFLD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Phytomedicine 医学-药学

CiteScore

10.30

自引率

5.10%

发文量

670

审稿时长

91 days

期刊介绍： Phytomedicine is a therapy-oriented journal that publishes innovative studies on the efficacy, safety, quality, and mechanisms of action of specified plant extracts, phytopharmaceuticals, and their isolated constituents. This includes clinical, pharmacological, pharmacokinetic, and toxicological studies of herbal medicinal products, preparations, and purified compounds with defined and consistent quality, ensuring reproducible pharmacological activity. Founded in 1994, Phytomedicine aims to focus and stimulate research in this field and establish internationally accepted scientific standards for pharmacological studies, proof of clinical efficacy, and safety of phytomedicines.